Hook & thesis
Hims & Hers (HIMS) is a beaten but operationally intact telehealth platform where U.S. revenue momentum appears to be coming back. The stock now trades around $30.37, well below its $65 52-week high, after a regulatory scare on 07/29/2026 that precipitated a near-term share price shock. That sell-off opened a clear tactical opportunity: the company generates positive free cash flow, has a sub-3x EV/sales multiple, and recent technicals suggest buyers are returning.
We are upgrading HIMS to a long trade idea. The combination of (1) U.S. revenue reacceleration, (2) free cash flow of $74.4M, (3) attractive relative valuation against its own prior highs, and (4) a technical base around the $28-$31 range supports an asymmetric upside to $40 over a long-term window (180 trading days) with a defined $25 stop.
What the company does and why the market should care
Hims & Hers operates a telehealth consultation platform connecting consumers with clinicians for mental health, sexual health, dermatology and primary care. The model is direct-to-consumer, recurring and increasingly integrated across services - a format that can drive higher lifetime value if privacy and billing issues are managed. For investors, two fundamental drivers matter: top-line growth from U.S. consumer adoption and improving monetization per user (prescriptions, subscriptions and ancillary services). When those drivers are together, the business can convert rapidly to consistent free cash flow.
Backing the argument with the numbers
Key financial and market stats support a constructive view:
- Current price: $30.37 and market cap roughly $7.08B.
- Valuation: price-to-sales is 2.6 and enterprise value-to-sales is 2.89 - levels that reflect compression from prior highs but still leave room for re-rating if growth normalizes.
- Profitability and cash: reported free cash flow of $74.44M, and a price-to-free-cash-flow near 90x by one metric - but that metric is misleading given the company recently reaccelerated revenues and is showing improving operating leverage.
- Balance sheet: current ratio 0.93 and quick ratio 0.87 suggest tight working capital, and debt-to-equity of 4.21 indicates meaningful leverage - both items to monitor closely.
- Earnings: last reported EPS was negative at -$0.61, but consensus and recent commentary point to earnings and revenue acceleration (one note cites expected quarterly revenue growth near ~49% and EPS growth of ~16.7% in the near term), indicating improving margins from the revenue side.
- Technicals and flows: the 10-, 20- and 50-day moving averages ($29.06, $28.52, $29.43) track the current price closely; RSI at 55 shows room before overbought territory and MACD histogram turned positive, indicating bullish momentum.
- Short interest: roughly 52.9M shares as of 09/15/2026 (about 25% of float) - a high short base that can amplify upside on supportive fundamentals or news.
Valuation framing
HIMS trades at EV/sales of about 2.9 and P/S of 2.6 today. Those multiples reflect a market that has priced in regulatory uncertainty and execution risk. Compare that to the stock's $65 52-week high (10/15/2025) where optimism around growth and multiple expansion was priced in. The current multiple is materially lower, and with positive free cash flow ($74.4M) plus revenue reacceleration, the path to a multiple re-rating is reasonable if management proves that U.S. growth is sustainable and privacy/billing issues are contained.
Qualitatively, telehealth peers have traded at a wide range of multiples depending on growth cadence and profitability. HIMS' current multiple looks attractive if it can sustain mid-to-high-teens EPS improvement and high-single-digit to double-digit organic revenue growth over the next 12 months.
Catalysts
- Quarterly results confirming U.S. revenue reacceleration and margin expansion - a clean beat would drive multiple re-expansion.
- Positive or constructive regulatory developments around the FTC lawsuit - any settlement framework or clarifying guidance that limits fines or structural remedies should reduce headline risk.
- Operational updates showing higher ARPU (up-sell of subscription services or higher prescription conversion), which would validate the monetization thesis.
- Reduction in short interest or evidence of improved institutional buying; with ~25% of the float short at mid-September, a short-covering move could amplify upside.
- Partnerships or product launches in core categories (mental health, dermatology) that accelerate customer acquisition efficiency.
Trade plan - entry, target, stop, horizon
| Action | Price | Horizon | Risk level |
|---|---|---|---|
| Entry | $30.37 | long term (180 trading days) | medium |
| Target | $40.00 | ||
| Stop | $25.00 |
Rationale: enter at $30.37 to participate immediately in the recovery; target $40 reflects a ~32% upside driven by multiple re-rating and continued revenue acceleration; stop $25 references the post-FTC trough on 07/29/2026 and limits capital at risk if regulatory damages or operational deterioration continues.
Why this setup is attractive now
Two forces are at work in HIMS: headline-driven valuation compression and an operational recovery that is showing in cash flow. The stock’s 52-week low and high ($13.74 on 02/24/2026 and $65.30 on 10/15/2025) highlight the volatility; right now the market is pricing in substantial execution and regulatory risk. If the company can prove that the U.S. business is reaccelerating and that privacy/billing issues are manageable, we think the market will ascribe a higher multiple to both revenue and free cash flow.
Risks and counterarguments
- Regulatory/legal risk: The FTC filed a complaint on 07/29/2026 alleging privacy and billing violations. This triggered a 14.73% one-day drop to $25.00 on 07/29/2026 and multiple class action filings. A significant penalty or restrictive remedy would materially impair growth and margins.
- Balance sheet and leverage: Current ratio 0.93 and debt-to-equity 4.21 indicate tight liquidity and leverage exposure. Adverse legal outcomes could stress cash and force dilutive financing.
- Execution risk on monetization: If ARPU and prescription conversion do not improve as expected, free cash flow could stall and the valuation re-rating will not occur.
- High short interest: While a short base can fuel rallies, it also signals that many market participants are skeptical; negative operational prints could produce rapid downside via deleveraging and forced selling.
- Counterargument: The regulatory headlines may be more persistent than the market expects. Even if HIMS stabilizes operations, legal and reputational costs could blunt user growth and conversion for many quarters, keeping multiples depressed. In that scenario the stock could revisit the low-$20s or lower, making the downside more pronounced than the current stop accounts for.
What would change our mind
Upside case would be confirmed by a sequence of events: a clear quarterly beat with accelerating U.S. revenue and improving margin cadence, tangible evidence that privacy/billing issues are being resolved with limited penalty, and sustained cash flow growth. That combination would make us more aggressive on target and more comfortable with adding size.
Conversely, our thesis would be invalidated if management reports persistent U.S. customer churn, materially larger-than-expected regulatory fines or structural remedies from the FTC (07/29/2026), or if liquidity issues force dilutive equity issuance. Any of those would push us to cut exposure or switch to a short stance.
Conclusion
HIMS is a tactical upgrade based on a mix of operational resilience and valuation opportunity. The company generates positive free cash flow, has early signs of U.S. revenue reacceleration, and now trades at a multiple that assumes continued pain. With defined risk controls - entry at $30.37, stop at $25.00 and target at $40.00 over a long-term horizon (180 trading days) - the trade offers an asymmetric risk/reward profile for disciplined traders willing to monitor regulatory developments closely. This is a constructive, but conditional, upgrade: the path higher requires both execution and resolution or containment of the recent privacy/billing allegations.